Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation-Reference-Cited by-同舟云学术

Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation

Published:2005-04 Issue:2 Volume:304 Page:604-619
ISSN:0014-4827
Container-title:Experimental Cell Research
language:en
Short-container-title:Experimental Cell Research

Author:

Diermeier Simone,Horváth Gábor,Knuechel-Clarke Ruth,Hofstaedter Ferdinand,Szöllősi János,Brockhoff Gero

Publisher

Elsevier BV

Subject

Cell Biology

Reference54 articles.

1. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials;Slamon;Semin. Oncol.,2001

2. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens;Press;J. Clin. Oncol.,2002

3. Evaluating HER2 amplification and overexpression in breast cancer;Bartlett;J. Pathol.,2001

4. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer;Pegram;Cancer Treat. Res.,2000

5. Antibodies as molecular target-based therapy: trastuzumab;Tokuda;Int. J. Clin. Oncol.,2003

Cited by 142 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overexpression of antiapoptotic gene products and resistance to trastuzumab treatment of breast cancer;Overcoming Cancers Resistant to HER-2 Antibodies;2024

2. Immunoexpression of HER2 pathway related markers in HER2 invasive breast carcinomas treated with trastuzumab;Pathology - Research and Practice;2023-12

3. Development of High-Loading Trastuzumab PLGA Nanoparticles: A Powerful Tool Against HER2 Positive Breast Cancer Cells;International Journal of Nanomedicine;2023-11

4. HER2-positive breast cancer: cotargeting to overcome treatment resistance;Current Opinion in Oncology;2023-07-06

5. Identification of genetic and immune signatures for the recurrence of HER2-positive breast cancer after trastuzumab-based treatment;Breast Cancer Research and Treatment;2023-04-21